Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 17, 2021 - Issue 5
Submit an article Journal homepage
11,687
Views
17
CrossRef citations to date
0
Altmetric
Research Paper

Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL

Prakash K. Bhuyana Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1937-9658View further author information
ORCID Icon,
Michael Dallasa Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, USAView further author information
,
Kim Kraynyaka Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, USAView further author information
,
Timothy Herringa Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, USAORCID Iconhttps://orcid.org/0000-0002-3475-8616View further author information
ORCID Icon,
Matthew Morrowa Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, USAView further author information
,
Jean Boyera Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, USAView further author information
,
Susan Duffa Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, USAView further author information
,
Joseph Kima Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, USAView further author information
&
David B. Weinerb Wistar Institute, Philadelphia, PA, USAView further author information
 show all
Pages 1288-1293 | Received 02 Jul 2020, Accepted 07 Sep 2020, Published online: 11 Nov 2020

References

  • Bruni LAG, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S Human papillomavirus and related diseases in the world. Summary Report 17 June 2019. 2019.
  • Group TFIS. Supplement to: The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:SupplementalMaterial.
  • Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet (London, England). 2015;386(10008):2078–88. doi:10.1016/S0140-6736(15)00239-1.
  • Kyrgiou M, Athanasiou A, Paraskevaidi M, Mitra A, Kalliala I, Martin-Hirsch P, Arbyn M, Bennett P, Paraskevaidis E. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ (Clinical Research Ed). 2016;354:i3633.
  • Hollenberg RK, Krieger DR, Samuels R, Kraynyak K, Sylvester A, Morrow M, Boyer J, Dallas M, Bhuyan PK. Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population. Hum Vaccin Immunother. 2020;16(6):1404–1412.
  • Melnikow J, McGahan C, Sawaya GF, Ehlen T, Coldman A. Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. J Natl Cancer Inst. 2009;101:721–28. doi:10.1093/jnci/djp089.
  • Xiang L, Li J, Yang W, Xu X, Wu X, Wang H, Li Z, Yang H. Conization using an electrosurgical knife for cervical intraepithelial neoplasia and microinvasive carcinoma. PloS One. 2015;10:e0131790. doi:10.1371/journal.pone.0131790.
  • Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, Schünemann H, Paraskevaidis E, Arbyn M. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017;8:Cd008587.
  • Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136(2):189–97. doi:10.1016/j.ygyno.2014.11.076.
  • Renshaw AA, DiNisco SA, Minter LJ, Cibas ES. A more accurate measure of the false-negative rate of Papanicolaou smear screening is obtained by determining the false-negative rate of the rescreening process. Cancer. 1997;81:272–76. doi:10.1002/(SICI)1097-0142(19971025)81:5<272::AID-CNCR3>3.0.CO;2-P.
  • Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol. 1995;141:680–89. doi:10.1093/oxfordjournals.aje.a117485.
  • Mast TC, Zhu X, Demuro-Mercon C, Cummings HW, Sings HL, Ferris DG. Development and psychometric properties of the HPV Impact Profile (HIP) to assess the psychosocial burden of HPV. Curr Med Res Opin. 2009;25:2609–19. doi:10.1185/03007990903238786.
  • Long S, Leeman L. Treatment options for high-grade squamous intraepithelial lesions. Obstet Gynecol Clin North Am. 2013;40:291–316. doi:10.1016/j.ogc.2013.03.004.
  • Armarnik S, Sheiner E, Piura B, Meirovitz M, Zlotnik A, Levy A. Obstetric outcome following cervical conization. Arch Gynecol Obstet. 2011;283:765–69. doi:10.1007/s00404-011-1848-3.
  • Leimbacher B, Samartzis N, Imesch P, Dedes KJ, Fink D, Canonica C. Inpatient and outpatient loop electrosurgery excision procedure for cervical intraepithelial neoplasia: a retrospective analysis. Arch Gynecol Obstet. 2012;285:1441–45. doi:10.1007/s00404-011-2148-7.
  • Martirosian TE, Smith SC, Baras AS, Darracott MM. Depot medroxyprogesterone acetate: a risk factor for cervical stenosis after loop electrosurgical excisional procedure management of cervical intraepithelial neoplasia? J Low Genit Tract Dis. 2010;14:37–42. doi:10.1097/LGT.0b013e3181b0f73f.
  • ACOG. American College of Obstetricians and Gynecologists 2017. Frequently asked questions, FAQ100. Loop Electrosurgical Excision Procedure (LEEP). 2017.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.